Celgene halts Revlimid trial in prostate cancer

Celgene's bid to expand use of Revlimid as a prostate cancer treatment just hit a major snag. The company stopped a Phase III trial after an independent monitoring committee determined that adding Revlimid to standard therapy wouldn't significantly boost patient survival.

Revlimid is a blockbuster performer for Celgene ($CELG), with expected 2011 revenues of more than $3 billion. It's approved for relapsed and refractory multiple myeloma and for certain anemia patients, and, if the company gets its way, will soon be cleared for two new multiple myeloma uses.

Broadening Revlimid's use to prostate cancer could pump up sales even further. Celgene has been recruiting patients for trials in other solid-tumor cancers, such as bladder, brain, ovarian and kidney cancer. The halted trial--known as MAINSAIL--was evaluating Revlimid combined with docetaxel and prednisone in castrate-resistant prostate cancer patients.

- see the Celgene release
- read the Reuters piece
- get more from PMLive

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.